Clinical trial end points for high-grade glioma: the evolving landscape*

To review the strengths and weaknesses of primary and auxiliary end points for clinical trials among patients with high-grade glioma (HGG). Recent advances in outcome for patients with newly diagnosed and recurrent HGG, coupled with the development of multiple promising therapeutics with myriad anti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reardon, David A., Galanis, Evanthia, DeGroot, John F., Cloughesy, Timothy F., Wefel, Jeffrey S., Lamborn, Kathleen R., Lassman, Andrew B., Gilbert, Mark R., Sampson, John H., Wick, Wolfgang, Chamberlain, Marc C., Macdonald, David R., Mehta, Minesh P., Vogelbaum, Michael A., Chang, Susan M., Van den Bent, Martin J., Wen, Patrick Y.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2011
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3064608/
https://ncbi.nlm.nih.gov/pubmed/21310734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq203
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados